Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
86.4M
-
Shares change
-
+4.52M
-
Total reported value, excl. options
-
$418M
-
Value change
-
-$1.55M
-
Put/Call ratio
-
0.06
-
Number of buys
-
81
-
Number of sells
-
-60
-
Price
-
$4.84
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2019
192 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2019.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.4M shares
of 236M outstanding shares and own 36.57% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (24.5M shares), BlackRock Inc. (10.2M shares), STATE STREET CORP (5.8M shares), Nantahala Capital Management, LLC (5.79M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), VANGUARD GROUP INC (5.17M shares), Novo Holdings A/S (3.1M shares), NUVEEN ASSET MANAGEMENT, LLC (1.63M shares), Point72 Asset Management, L.P. (1.62M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.5M shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.